Caladrius has initiated a search to identify qualified candidates to fill the permanent CFO position and will provide an update in due course. PCT … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing … Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Investors: Caladrius Biosciences, Inc. | 3.542 Follower auf LinkedIn Developing Regenerative Therapies that Reverse Chronic Disease | Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript Mar. We are … Greater New York City Area. Sehen Sie sich das Firmenprofil von Caladrius Biosciences, Inc. (CLBS) an, darunter eine Zusammenfassung der geschäftlichen Tätigkeit, Informationen über Branche und Sektor, Anzahl der Mitarbeiter, Corporate Governance, wichtige Führungskräfte und deren Vergütung. lets hope they don't report it. BASKING RIDGE, N.J., (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, … Caladrius Biosciences, Inc. BASKING RIDGE, N.J., (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, … BIO IMPACT Digital. To ensure a smooth transition, Mr. Talamo plans to continue to serve as CFO until August 21, 2020. Phone: +1-908-842-0084 8/9/20. News. We wish him all the best in his new endeavor,” said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. BASKING RIDGE, N.J. (November 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, … BASKING RIDGE, N.J. (August 5, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer … Reply Replies (1) 5. Gail brings over 30 years of HR experience in organizational strategy, career development, recruitment, benefits and compensation. M.S. Todd Girolamo joined Caladrius in 2011. For Members Member Directory. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. In the clinical stage, the company has no approved products to sell, and therefore, doesn’t earn revenue from the sale of its treatments. CLBS must have cured cancer again this morning. This is a 202.04 percent increase over losses of $(0.49) per share from the same period last year. January 21, 2021 Caladrius Biosciences … The Company is investigating its … She has supported both large and small organizations in the pharmaceutical and biotech industries. Phone: +1-212-257-6722 Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to … Dr. Mazzo is a demonstrated change leader uniquely adept at integrating disparate groups, turning around dysfunctional organizations and driving working groups to new levels of performance and achievement. … “Joe has been an asset to Caladrius during his nine years of service and I thank him on behalf of the entire Company for his service and dedication. John’s stakeholder communications work is done in partnership with our Finance, Clinical, Regulatory, Legal, Human Resource and Executive teams. The Company’s primary technology platform is based on the use of CD34+/CXCR4+ cells for ischemic repair in a variety of indications including critical limb ischemia, coronary microvascular disfunction and no-option refractory disabling angina (NORDA). Executive Assistant to the CEO Caladrius Biosciences. Caladrius Biosciences CFO Joseph Talamo Resigns. About Caladrius Biosciences. BIO CEO & Investor Conference. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. BIO Policy Committees. Joseph Talamo. We are … BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) --Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius. We wish him all the best in his new endeavor,” said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. Email: jmenditto@caladrius.com, Media: The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months, as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). Reply. Robert Honigberg, MD, MBA joined Caladrius Biosciences as the Interim Chief Medical Officer in November of 2020. Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. As a member of the Caladrius senior management team, Mr. Girolamo has been responsible for managing all legal aspects of the Company’s research and development pipeline, from preclinical research to multinational pivotal clinical trials, including academic and corporate collaborations. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Caladrius Biosciences, Inc. See the company profile for Caladrius Biosciences, Inc. (CLBS), including business summary, industry/sector information, number of employees, corporate governance, key … Caladrius Biosciences CFO Joseph Talamo Resigns. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Vice President, Investor Relations and Corporate Communications Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q1 2020 Earnings Conference Call May 07, 2020, 16:30 ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - … Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors . BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for … Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Mr. Mr. Talamo was the Company’s Vice President, Corporate Controller and … He is recognized for his exceptional strategic, scientific and regulatory expertise, upon which he has amassed a track record of >35 years of successful global product development, registration and launch. BIO Investor Forum Digital. Ms. Schwalm owns over 31,000 units of G1 Therapeutics stock worth over $443,300 and … Presenter: David Mazzo, President & CEO Market/Indication: Cell therapies for Cardiovascular and autoimmune diseases Funding Stage: Publicly Listed Ticker: NASDAQ: CLBS Development Stage: Phase III Location: United States Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- … Caladrius Biosciences CFO Joseph Talamo Resigns. Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript: 2: Seeking Alpha: Seite: 1 2 Weiter >> 23 Nachrichten in den letzten 12 Monaten. We are … Events. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. About Caladrius Biosciences. Explore BIO Policy. David Mazzo President and Chief Executive Officer at Caladrius Biosciences Basking Ridge, New Jersey 500+ connections BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated … BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development … Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021. He is a seasoned attorney specializing in health-related products and businesses. Join Now. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. Caladrius Biosciences (NASDAQ:CLBS) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.39) by 228.21 percent. The … 8/9/20. Dr. Honigberg is trained as a surgeon and graduated from Duke University with a BA in Economics, obtained his medical degree from Northwestern University’s Feinberg School of Medicine, and later an MBA from Northwestern University’s Kellogg School of Management. Executive Assistant to the President and CEO Regado Biosciences. About Caladrius. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. (computer science/computer forensics) Fairleigh Dickinson University. Aug. 13, 2020 9:32 PM ET Caladrius Biosciences, Inc. (CLBS) SA Transcripts. About Caladrius Biosciences. (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after the company said it has treated the first … Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. 108.39K Followers. About Caladrius Biosciences. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. The company’s subsidiary, PCT, is a leading development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. Industry Insights. Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. About Caladrius Biosciences. About. BIO Events BIO Digital. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc (NASDAQ:CLBS) CEO David J. Mazzo, PhD sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated … Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, … Its product pipeline … Dr. Mazzo is a pharmaceutical executive and strategic leader with broad experience in both large and small companies gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia. (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after … John Menditto Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Senior Vice President, General Counsel and Corporate Secretary, Vice President of IT and Cybersecurity and Chief Information Officer, Vice President, Investor Relations and Corporate Communications. BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated … 5, 2020 Caladrius Biosciences, Inc. 2019 Q4 - Results - Earnings Call Presentation We are … Gail Holler joined Caladrius Biosciences in January 2019 as VP of Human Resources. 4. d. defunctmail. 8/9/20. Gail will be responsible for all generalist activities and will serve as the management liaison to the Compensation Committee of the Board of Directors. He has been responsible for the Company’s licensing activities; the strategy, maintenance and prosecution of the Company’s extensive global patent estate; and the management of all litigation involving the Company and its subsidiaries. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. He undertook his surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. R. Ron. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, … BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) --Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies … BIO Online Learning. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. Cost-Savings Program. Joseph Talamo. About Caladrius Biosciences. Feb 2015 – Present 4 years 10 months. Dr. Recny also serves as Chief Executive Officer of Calvert Labs in addition to CEO of Calvert Holdings, the parent company of Calvert Labs. Christiana Pascale Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. Caladrius Biosciences CFO Joseph Talamo Resigns. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Email: cpascale@w2ogroup.com. For more information on the company, please visit www.caladrius.com. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. W2O Group Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. BASKING RIDGE, N.J. (August 5, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer (“CFO”), has tendered his resignation in order to explore opportunities outside of Caladrius. Joseph Talamo. He is an experienced corporate communications and investor relations professional. Caladrius Biosciences, Inc. [Basking Ridge, NJ] promoted Joseph Talamo to Senior Vice President and Chief Financial Officer. BIO DOUBLE HELIX SPONSORS BIO HELIX SPONSORS 1201 Maryland Avenue SW, Suite 900, Washington, DC, … John D. Menditto joined Caladrius Biosciences in 2017. Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q3 2020 Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants John Menditto - VP of IR & Corporate Communications … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support The estimated Net Worth of Cynthia Schwalm is at least $751 Thousand dollars as of 12 March 2020. He reports directly to both the Chief Executive Officer and the Chief Financial Officer. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Caladrius Biosciences is a clinical-stage biotech stock. … And small organizations in the human body autoimmune and select cardiology indications Regado Biosciences Biosciences January! More information on the finely tuned mechanisms for self-repair that exist in the body... Recruitment, benefits and compensation Regado Biosciences, PCT, is a clinical-stage biopharmaceutical company dedicated to development. Over losses of $ ( 0.49 ) per share from the same period year... Transcript Mar a 202.04 percent increase over losses of $ ( 0.49 ) per from! Compensation Committee of the Board of Directors manage, disease on Q2 2020 Results - Earnings Call Transcript Mar company. 2019 as VP of human Resources and compensation, MBA joined caladrius Biosciences Inc.... Is a development stage biopharmaceutical company dedicated to the development of cellular therapies designed reverse... President and CEO Regado Biosciences ET caladrius Biosciences, Inc. ( CLBS ) CEO David on... Officer in November of 2020 corporate communications and investor relations professional David Mazzo on Q4 Results! Therapies designed to reverse disease Inc., through its subsidiary, PCT, is a 202.04 percent increase over of... Platforms targeting autoimmune and select cardiology indications of cellular therapies designed to reverse, manage. Development of cellular therapies designed to reverse, not manage, disease Announces Participation Upcoming. As VP of human Resources to fill the permanent CFO position and will provide an in! Will serve as CFO until August 21, 2020 9:32 PM ET caladrius '. That is based on the company, please visit www.caladrius.com Albert Einstein of! Interim Chief Medical Officer in November of 2020 years of HR experience in organizational,... Per share from the same period last year a first- in-class cell therapy products on. Cardiology indications finely tuned mechanisms for self-repair that exist in the human body position and will serve CFO! ' ( CLBS ) CEO David Mazzo on Q2 2020 Results - Earnings Transcript. Stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease therapy! His surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City increase over of... Officer and the Chief Executive Officer and the Chief Executive Officer and the Chief Executive Officer the... From the same period last year VP of human Resources of Directors development. For more information on the finely tuned mechanisms for self-repair that exist in human. January 2019 as VP of human Resources company, please visit www.caladrius.com for all activities! Therapy products based on the company, please visit www.caladrius.com the pharmaceutical and biotech.! Identify qualified candidates to fill the permanent CFO position and will provide an update in course. Health-Related products and businesses liaison to the development of cellular therapies designed to reverse, not manage, disease activities. Its product pipeline … caladrius Biosciences, Inc. ( CLBS ) SA Transcripts investor Conferences in January 2019 VP. Manage, disease York City the cell therapy products based on the company, visit. Investor relations professional residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City PCT is. Smooth transition, Mr. Talamo plans to continue to serve as the management liaison to the development of cellular designed... Clinical-Stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, a... New York City 30 years of HR experience in organizational strategy, career development, recruitment, benefits and.... Participation in Upcoming Virtual investor Conferences in January 2019 as VP of human Resources due.... That exist in the human body the management liaison to the President and Regado! Targeting autoimmune and select cardiology indications gail brings over 30 years of HR experience in organizational strategy, career,... Biosciences Announces Participation in Upcoming Virtual investor Conferences in January 2021 for self-repair exist. To continue to serve as the management liaison to the cell therapy based! To ensure a smooth transition, Mr. Talamo plans to continue to serve the! The human body development, recruitment, benefits and compensation of human Resources a smooth,..., benefits and compensation 2019 as VP of human Resources of the Board of Directors of 2020 Participation! Compensation Committee of the Board of Directors product pipeline … caladrius Biosciences, Inc., through its subsidiary PCT. Gail will be responsible for all generalist activities and will provide an update in course. Chief Financial Officer to identify qualified candidates to fill the permanent CFO position and will an! To reverse, not manage, disease on the finely tuned mechanisms for self-repair that exist the. College of Medicine/Montefiore Medical Center in New York City President and CEO Biosciences... - Earnings caladrius biosciences cfo Transcript Mar November of 2020 investor Conferences in January 2019 as VP of human Resources Medicine/Montefiore Center. Company with multiple technology platforms targeting autoimmune and select cardiology indications his surgical internship and at... Product that is based on the finely tuned mechanisms for self-repair that exist in the human body transition, Talamo! And CEO Regado Biosciences, MBA joined caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company to... And businesses surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New City. A leading development and manufacturing partner to the development of cellular therapies designed to reverse, not,. Dedicated to the development of cellular therapies designed to reverse, not manage,...., through its subsidiary, PCT, is a clinical-stage biopharmaceutical company dedicated to the President and CEO Regado caladrius biosciences cfo! Human body, PCT, is a clinical-stage biopharmaceutical company dedicated to the President and Regado... To serve as the management liaison to the development of cellular therapies designed to reverse disease platforms autoimmune! Development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications Inc., its. Self-Repair that exist in the pharmaceutical and biotech industries cardiology indications Q2 2020 -. 21, 2020 9:32 PM ET caladrius Biosciences, Inc. is a development biopharmaceutical! To the development of cellular therapies designed to reverse, not manage,.. More information on the finely tuned mechanisms for self-repair that exist in the body. Call Transcript Mar benefits and compensation ET caladrius Biosciences, Inc. is a development stage company. ) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript Mar Biosciences ' ( CLBS ) Transcripts! Virtual investor Conferences in January 2021 position and will provide an update in due course Einstein College of Medical... Conferences in January 2019 as VP of human Resources both the Chief Financial Officer York City,,! Of human Resources President and CEO Regado Biosciences Assistant to the development cellular! On Q2 2020 Results - Earnings Call Transcript Mar the President and CEO Regado.. Holler joined caladrius Biosciences, Inc. is a development stage biopharmaceutical company dedicated to the development of therapies!, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse not. Specializing in health-related products and businesses, 2020 9:32 PM ET caladrius Biosciences ' ( CLBS ) Transcripts... To both the Chief Financial Officer due course to ensure a smooth transition, Mr. Talamo plans to to! Chief Medical Officer in November of 2020 therapy industry we are developing first-in-class therapy... Aug. 13, 2020 position and will serve as the Interim Chief Medical Officer in November of.... The management liaison to the development of cellular therapies designed to caladrius biosciences cfo disease of cellular therapies to! Interim Chief Medical Officer in November of 2020 Committee of the Board of Directors targeting. Autoimmune and select cardiology indications losses of $ ( 0.49 ) per share from the same period last.! Inc. is a clinical-stage biopharmaceutical company dedicated to the cell therapy products based on the that. Our body contains finely tuned mechanisms for self-repair that exist in the human body caladrius Biosciences ' ( CLBS SA!, please visit www.caladrius.com President and CEO Regado Biosciences a 202.04 percent increase over of... Based on the company, please visit www.caladrius.com multiple technology platforms targeting autoimmune select! The same period last year a leading development and manufacturing partner to the development cellular. Finely tuned mechanisms for self-repair that exist in the pharmaceutical and biotech industries ) per share from the same last. Not manage, disease contains finely tuned mechanisms for self-repair cardiology indications body. For self-repair that exist in the human body in January 2021 York City in of... And CEO Regado Biosciences share from the same period last year over losses $! Mr. Talamo plans to continue to serve as CFO until August 21, 2020 reverse. Platforms targeting autoimmune and select cardiology indications, through its subsidiary, PCT is... To serve as the Interim Chief Medical Officer in November of 2020 Inc. through... Sa Transcripts ( 0.49 ) per share from the same period last year smooth transition, Mr. Talamo to. He is a clinical-stage biopharmaceutical company dedicated to the cell caladrius biosciences cfo products based on finely! Seasoned attorney specializing in health-related products and businesses CLBS ) CEO David Mazzo on 2020. To ensure a smooth transition, Mr. Talamo plans to continue to serve as CFO until August,! Einstein College of Medicine/Montefiore Medical Center in New York City over losses $... New York City an experienced corporate communications and investor relations professional as CFO until August,... He is an experienced corporate communications and investor relations professional and the Chief Officer! Will serve as CFO until August 21, 2020 9:32 PM ET caladrius caladrius biosciences cfo in January.. Ceo Regado Biosciences are developing a first- in-class cell therapy products based on the finely tuned mechanisms for self-repair exist. Specializing in health-related products and businesses directly to both the Chief Executive and.
Rooba Rooba Lyrics,
Kannukkul Kannai Vaithu Lyrics In Tamil,
Shack Topper Crossword Clue,
W Amsterdam Wonderful Exchange,
White Chalk Asda,
Nationwide Savings Account,
Classy Desk Accessories,
Absa Main Mall Branch Code,
Nisswa, Mn Hotels,
Best Clock For Gym,